<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4930">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209998</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02619-48</org_study_id>
    <nct_id>NCT04209998</nct_id>
  </id_info>
  <brief_title>New Oxymetry Indices in Critical Limb Ischemia</brief_title>
  <acronym>NOVICE</acronym>
  <official_title>New Oxymetry Indices in Critical Limb Ischemia (French Original Title is &quot;Nouveaux Indices Oxymétriques Chez Les Patients Vus Pour Suspicion d'Ischémie Critique du membrE inférieur&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcutaneous oxygen tension (TcpO2) at rest, sensitized by oxygen inhalation tests, is&#xD;
      widely applied for the evaluation of chronic critical limb ischemia (CLI). If foot TcpO2&#xD;
      measurements are good prognostic factors of the risk of amputation or the probability of&#xD;
      wound healing without amputation, they have never proven their hability to estimate the risk&#xD;
      of death in patients with critical limb ischemia. On the one hand, studies have considered&#xD;
      only the response observed on legs without considered the thoracic variations. On the other&#xD;
      hand, the variability of the TcpO2 signal has never been analyzed as a prognostic factor.&#xD;
&#xD;
      The objective of the NOVICE study is therefore to assess, first, whether the variability of&#xD;
      resting TcPO2 values at thoracic probe as well as at affected limb probe is a&#xD;
      morbidity-mortality prognostic factor and secondly, to evaluate during the oxygen tests, if&#xD;
      the measurement of the amplitude of the distal responses in ischemic zone compared to the&#xD;
      response observed in thoracic probe is a prognostic factor of morbi-mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an ambispective (both retrospective and prospective) cohort study in which any major&#xD;
      patient, referred for resting (transcutyaneous oxygen pressure = TcpO2) for suspicion of&#xD;
      critical limb ischemia, is included retrospectively and prospectively from November 2018 to&#xD;
      October 2020. Tcpo2 recording are analysed to determine specific parameters (signal&#xD;
      variability and response top oxygen). A morbidity-mortality follow-up is carried out between&#xD;
      12 and 15 months after the Tcpo2 measurement. A Kaplan Mayer study of these indices against&#xD;
      MALE (major adverse lower limb events ) and MACE(Major adverse cardiovascular events) will be&#xD;
      carried out.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>presence of MACE (major adverse cardiovascular event) following the oximetry test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>12 moths</time_frame>
    <description>presence of MALE (major adverse lower limb event) following the oximetry test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (intermediate analysis)</measure>
    <time_frame>6 months minimal follow-up</time_frame>
    <description>Mortality all causes (intermediate analysis prior to Covid interference)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>transcutaneous oximetry</intervention_name>
    <description>Analysis of transcutaneous oximetry (Tcpo2) in terme of variability at rest and of response to oxygen inhalation</description>
    <other_name>oxygen inhalation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred for Tcpo2 recording for suspicion of critical limb ischemia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspicion of Critical limb ischemia&#xD;
&#xD;
          -  Reffered for Tcpo2 Absence of rebuttal to the use of the data by the patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No available tcpo2 recording&#xD;
&#xD;
          -  Rejection of the follow up by the patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABRAHAM Pierre, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital in Angers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABRAHAM Pierre, MD PhD</last_name>
    <phone>+33241353689</phone>
    <email>explovasculaire@chu-angers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier universitaire</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Abraham, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Abraham, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transcutaneous oximetry</keyword>
  <keyword>oxygen</keyword>
  <keyword>peripheral artery disease</keyword>
  <keyword>follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

